Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine.
López-Macías C, Torres M, Armenta-Copca B, Wacher NH, Galindo-Fraga A, Castro-Castrezana L, Colli-Domínguez AA, Cervantes-Trujano E, Rucker-Joerg IE, Lozano-Patiño F, Rivera-Alcocer JJ, Simón-Campos A, Sánchez-Campos EA, Aguirre-Rivero R, Muñiz-Carvajal AJ, Del Carpio-Orantes L, Márquez-Díaz F, Rivera-Hernández T, Torres-Flores A, Ramírez-Martínez L, la Rosa GP, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Carranza C, Juárez E, Zamudio-Meza H, Carreto-Binaghi LE, Viettri M, Romero-Rodríguez D, Palencia A, Sarfati-Mizrahi D, Sun W, Chagoya-Cortés HE, Castro-Peralta F, Palese P, Krammer F, García-Sastre A, Lozano-Dubernard B. López-Macías C, et al. Among authors: simon campos a. Sci Adv. 2025 Jun 27;11(26):eadq2887. doi: 10.1126/sciadv.adq2887. Epub 2025 Jun 27. Sci Adv. 2025. PMID: 40577471 Free PMC article. Clinical Trial.
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Ansari W, Harrington MA, Simón-Campos A, Chew KW, Pypstra R, Rusnak JM. Hammond J, et al. Among authors: simon campos a. Clin Infect Dis. 2025 Feb 24;80(2):323-330. doi: 10.1093/cid/ciae551. Clin Infect Dis. 2025. PMID: 39523543 Free PMC article. Clinical Trial.
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).
Horga A, Saenz R, Yilmaz G, Simón-Campos A, Pietropaolo K, Stubbings WJ, Collinson N, Ishak L, Zrinscak B, Belanger B, Granier C, Lin K, C Hurt A, Zhou XJ, Wildum S, Hammond J. Horga A, et al. Among authors: simon campos a. Future Virol. 2023 Oct:10.2217/fvl-2023-0115. doi: 10.2217/fvl-2023-0115. Epub 2023 Nov 1. Future Virol. 2023. PMID: 37928891 Free PMC article.
Nirmatrelvir for Nonhospitalized Adults with Covid-19. Reply.
Hammond J, Bao W, Simón-Campos A. Hammond J, et al. Among authors: simon campos a. N Engl J Med. 2022 Aug 4;387(5):475-476. doi: 10.1056/NEJMc2206277. Epub 2022 Jul 20. N Engl J Med. 2022. PMID: 35857649 No abstract available.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Hammond J, et al. Among authors: simon campos a. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.